Business Context and Reporting Period
This Form 6-K filing by Banco Bradesco S.A. (Bradesco) reports a related-party transaction disclosed on April 7, 2022. The filing pertains to an investment agreement entered into by Bradesco's indirect subsidiary, Bradesco Gestão de Saúde S.A. (Bradesco Gestão), with Sabin Ventures Ltda. and Fleury S.A.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. It focuses exclusively on the terms of a specific investment transaction:
- Initial Investment: Subscription of 25,000 quotas in Kortex Ventures Fundo de Investimento em Participações I (Kortex FIP) for R$25,000,000.00.
- Initial Ownership Stake: 12.5% interest in Kortex FIP following the initial subscription.
- Planned Additional Investment: Up to R$35,500,000.00 via a subsequent private offering.
- Target Ownership Stake: 23% of Kortex FIP issue quotas after the additional subscription.
- Investment Focus: Startups in digital health, diagnostic medicine, and personalized medicine.
Material Changes and Transaction Details
The filing details a Binding Investment Commitment Agreement subject to approval by CADE (Brazilian Administrative Council for Economic Defense). The transaction structure results in the following ownership distribution in Kortex FIP:
- Fleury S.A.: 54%
- Bradesco Gestão: 23%
- Sabin Ventures Ltda.: 23%
Bradesco holds a 29.98% stake in Fleury S.A. through its subsidiary Bradesco Diagnóstico em Saúde S.A., establishing the related-party nature of the transaction.
Management Commentary and Risks
Management asserts that the transaction observed commutative conditions, noting that Bradesco Gestão will subscribe to quotas at an amount at least equivalent to the price paid by Fleury and Sabin. The agreement received applicable internal approvals adhering to governance, ethics, and transparency practices without conflicts of interest.
Risks and Contingencies:
- The transaction is contingent upon approval by CADE.
- Forward-looking statements regarding future economic circumstances and investment performance are subject to risks and uncertainties, with no guarantee that expected results will occur.
Investor Verification Checklist
- Verify the status of CADE approval for the Kortex FIP investment.
- Confirm the final closing amount of the additional R$35,500,000.00 private offering.
- Review the valuation methodology used to determine the subscription price for the Kortex FIP quotas.
- Monitor the performance of the digital health and diagnostic medicine startups within the Kortex FIP portfolio.